Physician profile
Han Vo
NPI 1790170173
$8,708.12
in general payments reported to CMS, 2019-2025
38 companies · $933 in 2025
The $933 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $569 · 2022: $1,487 · 2023: $2,554 · 2024: $2,719 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,206.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,612.53 | 2019-2025 | Farxiga, Airsupra, Evusheld |
| Lilly USA, LLC | $980.81 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $915.30 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $914.72 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Abbvie INC. | $883.54 | 2023-2025 | Qulipta, Ubrelvy, Botox |
| Amgen INC. | $618.71 | 2022-2025 | Otezla, Repatha, Enbrel |
| Glaxosmithkline, LLC. | $310.95 | 2022-2025 | Shingrix, Bexsero, Arexvy |
| Abbott Laboratories | $286.70 | 2023-2024 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $286.50 | 2023-2024 | Quviviq |
| Gilead Sciences, INC. | $176.51 | 2019-2020 | |
| Sk Life Science, INC. | $158.87 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $156.38 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Allergan, INC. | $148.93 | 2020 | |
| Exact Sciences Corporation | $140.52 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $134.43 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $128.71 | 2020-2025 | |
| Si-Bone, INC. | $125.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $73.58 | 2019-2022 | |
| Biogen, INC. | $54.16 | 2023 | Vumerity, Avonex, Tysabri |
| Sanofi Pasteur INC. | $46.75 | 2020-2024 | |
| Lucid Diagnostics INC. | $45.03 | 2022 | |
| Myriad Genetic Laboratories, INC. | $44.97 | 2023 | Myrisk |
| Amarin Pharma, INC. | $43.73 | 2020 | |
| Xeris Pharmaceuticals, INC. | $40.51 | 2022 | |
| Mdd US Operations, LLC | $39.36 | 2023 | Gocovri |
| Seqirus USA INC | $36.62 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $34.13 | 2022-2023 | Ajovy |
| Bayer Healthcare Pharmaceuticals INC. | $32.52 | 2025 | |
| Averitas Pharma INC. | $32.20 | 2024 | Qutenza |
| Tanabe Pharma America, INC. | $29.46 | 2024 | |
| Bausch Health US, LLC | $26.45 | 2023 | Aplenzin |
| Dexcom, INC. | $25.37 | 2023 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $24.21 | 2024 | Heplisav-B |
| Alexion Pharmaceuticals, INC. | $23.88 | 2020 | |
| Hologic Sales and Service, LLC | $22.59 | 2022 | |
| Kaleo, INC. | $21.93 | 2022 | |
| Medtronic, INC. | $19.00 | 2023 | Intellis Adaptivestim |
| Fidia Pharma USA INC. | $12.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Han Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.